Indian pharmaceutical stocks declined in early trade on April 2, 2026, with most listed companies showing losses on both BSE and NSE.
As of approximately 9:23-9:25 AM IST, the majority of pharma scrips were trading in the red. Notable declines included:
- Sun Pharma: BSE ₹1,644.00 (-4.89%), NSE ₹1,653.20 (-4.36%)
- Aurobindo Pharma: BSE ₹1,290.70 (-3.83%), NSE ₹1,282.00 (-4.48%)
- Biocon: BSE ₹348.10 (-4.67%), NSE ₹348.20 (-4.65%)
- Glenmark Pharma: BSE ₹2,010.85 (-4.26%), NSE ₹2,004.60 (-4.59%)
- IPCA Labs: BSE ₹1,445.45 (-4.34%), NSE ₹1,452.20 (-3.71%)
- EMCURE Pharmaceuticals: BSE ₹1,522.00 (-4.20%), NSE ₹1,534.10 (-3.52%)
- Granules India: BSE ₹605.90 (-3.55%), NSE ₹607.40 (-3.30%)
- Lupin: BSE ₹2,197.35 (-3.35%), NSE ₹2,194.40 (-3.54%)
- Divis Laboratories: BSE ₹5,717.90 (-3.20%), NSE ₹5,718.50 (-3.18%)
- Dr. Reddy’s Lab: BSE ₹1,170.10 (-3.23%), NSE ₹1,175.20 (-2.84%)
Other stocks such as Alembic Pharma (-2.96% to -3.11%), Alkem Laboratories (-2.01% to -2.06%), Cipla (-1.91% to -2.14%), and Zydus Lifesciences (-2.51% to -2.59%) also posted losses. A small number of names, including Corona Remedies (+1.39% on BSE), Indoco Remedies (+1.59% on BSE), RPG Life Sciences (+1.55% on BSE), and Unichem Lab (+1.94% on BSE), traded higher.
Broader market context showed weakness, with the Nifty 50 at ₹22,252.15 (-1.88%) and BSE Sensex at ₹71,754.64 (-1.89%) around the same time.
Prices are indicative of early morning trade and remain subject to change. Investors should refer to official exchange data for real-time updates.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.